MedTrace Logo

Efficacy of Organoid-Based Chemotherapy Drug Precision Screening to Guide Treatment for Thyroid Cancer

NCT06713057 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2024-12-03

No results posted yet for this study

Summary

The current study aims to explore the potential advantages of chemotherapy that is implemented based on drug sensitivity testing. This pertains to individuals with locally advanced or metastatic poorly differentiated or anaplastic thyroid cancer who have undergone conventional therapy in the past or unresectable patients .

Conditions

Interventions

DRUG

Cyclophosphamide+Pemetrexed+5-Fluorouracil

IV or PO

DRUG

Cyclophosphamide+Doxorubicin+5-Fluorouracil

IV or PO

DRUG

Vindesine + Cisplatin

IV or PO

DRUG

Doxorubicin + Cisplatin

IV or PO

DRUG

Doxorubicin + Cyclophosphamide + Cisplatin

IV or PO

DRUG

Docetaxel + Doxorubicin

IV or PO

DRUG

Paclitaxel + Carboplatin

IV or PO

DRUG

Paclitaxel + Doxorubicin

IV or PO

DRUG

Paclitaxel + Cisplatin

IV or PO

DRUG

Gemcitabine alone

IV or PO

Sponsors & Collaborators

  • West China Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-01
Primary Completion
2025-12-01
Completion
2026-07-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06713057 on ClinicalTrials.gov